1. |
Congdon NG, Friedman DS, Lietman T. Important causes of visual impairment in the world today. JAMA 2003; 290: 2057-60.
|
|
2.Xie X, Xu L, Yang H, et al. Frequency of diabetic retinopathy in the adult population in China: the Beijing Eye Study 2001. Int Ophthalmol 2009; 29: 485-93.
|
|
3.Hanis CL, Hallman D. Genetics of diabetic retinopathy. Curr Diab Rep 2006; 6: 155-61.
|
|
4.Demaine A, Cross D, Millward A. Polymorphisms of the aldose reductase gene and susceptibility to retinopathy in type 1 diabetes mellitus. Invest Ophthalmol Vis Sci 2000; 41: 4064-8.
|
|
5.Arar NH, Freedman BI, Adler SG, et al. Heritability of the severity of diabetic retinopathy: the find-eye study. Invest Ophthalmol Vis Sci 2008; 49: 3839-5.
|
|
6.Olmos P, Futers S, Acosta AM, et al. (AC)23 [Z-2] polymorphism of the aldose reductase gene and fast progression of retinopathy in Chilean type 2 diabetics. Diabetes Res Clin Pract 2000; 47: 169-76.
|
|
7.Li Q, Xie P, Huang J, et al. Polymorphisms and functions of the aldose reductase gene 5' regulatory region in Chinese patients with type 2 diabetes mellitus. Chin Med J (Engl) 2002; 115: 209-13.
|
|
8.Greene DA, Lattimer SA, Sima AA. Sorbitol, phosphoino- sitides, and sodium-potassium-atpase in the pathogenesis of diabetic complications. N Engl J Med 1987; 316: 599-606.
|
|
9.Lewko B, Latawiec E, Maryn A, et al. Osmolarity and glucose differentially regulate aldose reductase activity in cultured mouse podocytes. Exp Diabetes Res 2011: 278963.
|
|
10.Abhary S, Burdon KP, Laurie KJ, et al. Aldose reductase gene polymorphisms and diabetic retinopathy susceptibility. Diabetes Care 2010; 33: 1834-6.
|
|
11.Katakami N, Kaneto H, Takahara M, et al. Aldose reductase c-106t gene polymorphism is associated with diabetic retinopathy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2011; 92: e57-60.
|
|
12.Ng DPK. Human genetics of diabetic retinopathy: current perspectives. J Ophthalmol 2010 [cited 2012 Jul 13]. Available from: http://www.hindawi.com/journals/joph/2010/1725 93/
|
|
13.Moczulski DK, Scott L, Antonellis A, et al. Aldose reductase gene polymorphisms and susceptibility to diabetic nephropathy in type 1 diabetes mellitus. Diabet Med 2000; 17: 111-8.
|
|
14.Neamat-Allah M, Feeney SA, Savage DA, et al. Analysis of the association between diabetic nephropathy and polymorphisms in the aldose reductase gene in type 1 and type 2 diabetes mellitus. Diabet Med 2001; 18: 906-14.
|
|
15.Wang Y, Ng MC, Lee SC, et al. Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes. Diabetes Care 2003; 26: 2410-5.
|
|
16.Makiishi T, Araki S, Koya D, et al. C-106T polymorphism of AKR1B1 is associated with diabetic nephropathy and erythrocyte aldose reductase content in Japanese subjects with type 2 diabetes mellitus. Am J Kidney Dis 2003; 42: 943-51.
|
|
17.Sivenius K, Niskanen L, Voutilainen-Kaunisto R, et al. Aldose reductase gene polymorphisms and susceptibility to microvascular complications in type 2 diabetes. Diabet Med 2004; 21: 1325-33.
|
|
18.Sivenius K, Pihlajamäki J, Partanen J, et al. Aldose reductase gene polymorphisms and peripheral nerve function in patients with type 2 diabetes. Diabetes Care 2004; 27: 2021-6.
|
|
19.Gosek K, Moczulski D, Zukowska-Szczechowska E, et al. C-106t polymorphism in promoter of aldose reductase gene is a risk factor for diabetic nephropathy in type 2 diabetes patients with poor glycaemic control. Nephron Exp Nephrol 2005; 99: e63-7.
|
|
20.Kao YL, Donaghue K, Chan A, et al. A novel polymorphism in the aldose reductase gene promoter region is strongly associated with diabetic retinopathy in adolescents with type 1 diabetes. Diabetes 1999; 48: 1338-40.
|
|
21.Olmos P, Bastías MJ, Vollrath V, et al. C(-106)T polymorphism of the aldose reductase gene and the progression rate of diabetic retinopathy. Diabetes Res Clin Pract 2006; 74: 175-82.
|
|
22.Santos KG, Tschiedel B, Schneider J, et al. Diabetic retinopathy in Euro-Brazilian type 2 diabetic patients: relationship with polymorphisms in the aldose reductase, the plasminogen activator inhibitor-1 and the methylene- tetrahydrofolate reductase genes. Diabetes Res Clin Pract 2003; 61: 133-6.
|
|
23.Richeti F, Noronha RM, Waetge RT, et al. Evaluation of AC(n) and C(-106)T polymorphisms of the aldose reductase gene in Brazilian patients with dm1 and susceptibility to diabetic retinopathy. Mol Vis 2007; 13: 740-5.
|
|
24.Chaturvedi N, Sjoelie AK, Svensson A, et al. The Diabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design. J Renin Angiotensin Aldosterone Syst 2002; 3: 255-61.
|
|
25.Suganthalakshmi B, Anand R, Kim R, et al. Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy. Mol Vis 2006; 12: 336-41.
|
|
26.Abel K, Reneland R, Kammerer S, et al. Genome-wide snp association: identification of susceptibility alleles for osteoarthritis. Autoimmun Rev 2006; 5: 258-63.
|
|
27.Liu S, Chen HD, Makarevitch I, et al. High-throughput genetic mapping of mutants via quantitative single nucleotide polymorphism typing. Genetics 2010; 184: 19-26.
|
|
28.Fanelli A, Hadjadj S, Gallois Y, et al. Polymorphism of aldose reductase gene and susceptibility to retinopathy and nephropathy in caucasians with type 1 diabetes. Arch Mal Coeur Vaiss 2002; 95: 701-8.
|
|
29.Watarai A, Nakashima E, Hamada Y, et al. Aldose reductase gene is associated with diabetic macroangiopathy in Japanese type 2 diabetic patients. Diabet Med 2006; 23: 894-9.
|
|
30.So WY, Wang Y, Ng MC, et al. Aldose reductase genotypes and cardiorenal complications: an 8-year prospective analysis of 1,074 type 2 diabetic patients. Diabetes Care 2008; 31: 2148-53.
|
|
31.dos Santos KG, Canani LH, Gross JL, et al. The -106CC genotype of the aldose reductase gene is associated with an increased risk of proliferative diabetic retinopathy in Caucasian-Brazilians with type 2 diabetes. Mol Genet Metab 2006; 88: 280-4.
|
|
32.Looker HC, Krakoff J, Knowler WC, et al. Longitudinal studies of incidence and progression of diabetic retinopathy assessed by retinal photography in pima indians. Diabetes Care 2003; 26: 320-6.
|
|
33.Stratton IM, Kohner EM, Aldington SJ, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 2001; 44: 156-63.
|
|
34.van Leiden HA, Dekker JM, Moll AC, et al. Risk factors for incident retinopathy in a diabetic and nondiabetic population: the Hoorn study. Arch Ophthalmol 2003; 121: 245-51.
|
|
35.Chorny A, Lifshits T, Kratz A, et al. Prevalence and risk factors for diabetic retinopathy in type 2 diabetes patients in Jewish and Bedouin populations in southern Israel. Harefuah 2011; 150: 906-10, 935.
|
|
36.Thomas RL, Dunstan F, Luzio SD, et al. Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for wales: retrospective analysis. BMJ 2012; 344: e874.
|
|
37.U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-58.
|
|
38.Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, et al. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989; 32: 219-26.
|